Xiamen Amoytop Biotech Co., Ltd. (SHA: 688278)

Market Cap	29.85B
Revenue (ttm)	2.60B
Net Income (ttm)	740.69M
Shares Out	406.80M
EPS (ttm)	1.82
PE Ratio	40.31
Forward PE	29.30
Dividend	0.41 (0.56%)
Ex-Dividend Date	n/a

Volume	1,304,526
Open	73.83
Previous Close	73.40
Day's Range	73.01 - 74.78
52-Week Range	46.30 - 86.11
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 1,960
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2023, Xiamen Amoytop Biotech's revenue was 2.10 billion, an increase of 37.55% compared to the previous year's 1.53 billion. Earnings were 555.45 million, an increase of 93.52%.